## Abbreviations
The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome. _J. Clin. Med._**2024**, _13_, 5124. [CrossRef] [PubMed]
* _Gershon and Tack (2007)_ Gershon, M.D. ; Tack, J. The Serotonin Signaling System: From Basic Understanding to Drug Development for Functional GI Disorders. _Gastroenterology_**2007**, _132_, 397-414. [CrossRef] [PubMed]
* _Dunlop et al. (2005)_ Dunlop, S.P. ; Coleman, N.S. ; Blackshaw, E.; Perkins, A.C.; Singh, G.; Marsden, C.A. ; Spiller, R.C. Abnormalities of 5-Hydroxyryptamine Metabolism in Irritable Bowel Syndrome. _Clin. Gastroenterol. Hepatol._**2005**, \(3\), 349-357. [CrossRef]
* _Atkinson et al. (2006)_ Atkinson, W.; Lockhart, S.; Whorwell, P.J. ; Keevil, B.; Houghton, L.A. Altered 5-Hydroxytryptamine Signaling in Patients with Constipation- and Diarrhea-Predominant Irritable Bowel Syndrome. _Gastroenterology_**2006**, _130_, 34-43. [CrossRef]
* _Cremon et al. (2011)_ Cremon, C.; Carini, G.; Wang, B.; Vasina, V.; Cogliandro, R.F. ; De Giorgio, R.; Stanghellini, V.; Grundy, D.; Tonini, M.; De Ponti, F.; et al. Intestinal Serotonin Release, Sensory Neuron Activation, and Abdominal Pain in Irritable Bowel Syndrome. _Am. J. Gastroenterol._**2011**, _106_, 1290-1298. [CrossRef]
* _Rokkas (2021)_ Rokkas, T. Comparative Effectiveness of 5-Hydroxytryptamine 3 Receptor Antagonists in Irritable Bowel Syndrome: A Network Meta-Analysis of Randomized Controlled Studies. _Ann. Gastroenterol._**2021**, _34_, 535-546. [CrossRef]
* _Stasi et al. (2012)_ Stasi, C.; Rosselli, M.; Bellini, M.; Laffi, G.; Milani, S. Altered Neuro-Endocrine-Immunue Pathways in the Irritable Bowel Syndrome: The Top-down and the Bottom-up Model. _J. Gastroenterol._**2012**, _47_, 1177-1185. [CrossRef]
* _Gershon and Serotonin and Its Implication for the Management of Irritable Bowel Syndrome. _Rev. Gastroenterol. Disord._**2003**, \(3\) (Suppl S2)_, S25-S34. * Durk et al. (2005) Durk, T.; Panther, E.; Muller, T.; Sorichter, S.; Ferrari, D.; Pizzirani, C.; Di Virgilio, F.; Myrtek, D.; Norgauer, J.; Idzko, M. 5-Hydroxytryptamine Modulates Cytokine and Chemokine Production in LPS-Primed Human Monocytes via Stimulation of Different 5-HTR Subtypes. _Int. Immunol._**2005**, _17_, 599-606. [CrossRef]
* Dinarello (1996) Dinarello, C.A. Biologic Basis for Interleukin-1 in Disease. _Blood_**1996**, _87_, 2095-2147. [CrossRef]
* Vezza et al. (2016) Vezza, T.; Rodriguez-Nogales, A.; Aligieri, F.; Urtilla, M.; Rodriguez-Cabezas, M.; Galvez, J. Flavonoids in Inflammatory Bowel Disease: A Review. _Nutrients_**2016**, \(8\), 211. [CrossRef] [PubMed]
* Han et al. (2019) Han, W.; Xie, B.; Li, Y.; Shi, L.; Wan, J.; Chen, X.; Wang, H. Orally Deliverable Nanotherapeutics for the Synergistic Treatment of Colitis-Associated Colorectal Cancer. _Thernostics_**2019**, \(9\), 7458-7473. [CrossRef] [PubMed]
* Zhang et al. (2020) Zhang, Z.; Dong, L.; Jia, A.; Chen, X.; Yang, Q.; Wang, Y.; Wang, Y.; Liu, R.; Cao, Y.; He, Y.; et al. Glucocorticoids Promote the Onset of Acute Experimental Colitis and Cancer by Upregulating MTOR Signaling in Intestinal Epithelial Cells. _Cancers_**2020**, _12_, 945. [CrossRef] [PubMed]
* Pu et al. (2021) Pu, J.; Zhou, X.; Liu, J.; Hou, P.; Ji, M. Therapeutic Potential and Deleterious Effect of Glucocorticoids on Azoymethane/Dextran Sulfate Sodium-Induced Colorectal Cancer in Mice. _Am. J. Cancer Res._**2021**, _11_, 4866-4883. * Ma et al. (2018) Ma, H.-Q. ; Yu, T.-T.; Zhao, X.-J. ; Zhang, Y.; Zhang, H.-J. Fecal Microbial Dysbiosis in Chinese Patients with Inflammatory Bowel Disease. _World J. Gastroenterol._**2018**, _24_, 1464-1477. [CrossRef]
* Raza et al. (2011) Raza, H.; John, A.; Benedict, S. AcetylIsalicylic Acid-Induced Oxidative Stress, Cell Cycle Arrest, Apoptosis and Mitochondrial Dysfunction in Human Hepatoma HepG2 Cells. _Eur. J. Pharmacol._**2011**, _668_, 15-24. [CrossRef]
* Gao et al. (2024) Gao, J.; Li, J.; Luo, Z.; Wang, H.; Ma, Z. Nanoparticle-Based Drug Delivery Systems for Inflammatory Bowel Disease Treatment. _Drug Des. Devel. Ther._**2024**, _18_, 2921-2949.